

Household SARS-CoV-2 transmission and children: a network prospective study

Antoni Soriano-Arandes PhD^{*1}, Anna Gatell MD², Pepe Serrano MD², Mireia Biosca PhD³, Ferran Campillo MD⁴, Ramon Capdevila MD³, Anna Fàbrega MD⁵, Zulema Lobato MD⁶, Núria López MD/MSc⁷, Ana M^a Moreno MD⁸, Miriam Poblet MD⁹, Maria Teresa Riera-Bosch PhD¹⁰, Neus Rius MD/MSc¹¹, Montserrat Ruiz MD¹², Almudena Sánchez MD¹³, Cinta Valldepérez MD², Mònica Vilà PhD¹⁴, Valentí Pineda PhD¹⁵, Uxue Lazcano MSc¹⁶, Yesika Díaz MSc^{17,18}, Juliana Reyes-Urueña PhD^{17,19}, Pere Soler-Palacín PhD¹, for the COPEDI-CAT research group**

**COPEDI-CAT research group:

Marc García-Lorenzo MD¹¹, Lorena Braviz MD²⁰, Àngels Naranjo MD²¹, Olga Salvadó MD²², Silvia Burgaya MD²³, Lidia Aulet MD²⁴, Javier Cantero MD²⁵, Gloria Ruiz MD²⁶, Marina Fenoy MD/MSc²⁷, Abel Martínez-Mejías MD/MSc²⁷, Iris González MD²⁷, Anton Foguet MD⁴, Imma Bayona MD⁸, Guillermo García MD²⁸, Laia Solé MD²⁹, Clara Calbet MD³⁰, Mireia Carulla MD³¹, Neus Piquè MD³¹, Pilar Llobet PhD³², Berta Pujol MD³², Álvaro Díaz-Conradi PhD³³, Maria Esteller MD³⁴, Blanca Rosich MD³⁵, Arantxa Gómez MD³⁵, Anna M^a Ristol MD³⁶, Borja Guarch MD³⁷, Francesc Ripoll MD³⁸, Maria Chiné MD³⁹, Carlos Losana MD⁴⁰, Romina Conti MD¹⁵, Isabel Zambudio MD⁴¹, Mercè Escuer MD⁴², Joan Manuel Torres MD⁴³, Tomas Perez-Porcuna PhD⁴⁴, Emiliano Mora MD⁴⁵, Roger García-Puig MD⁴⁵, Silvia Prado MD⁴⁶, Daniel Gros MD⁴⁶, Mercè Giribet MD⁴⁷, Pili Villalobos MD⁴⁸, Dolors Canadell MD⁴⁹, Xavier Bruna MD⁵⁰, Elisenda Martínez-Carbonell MSc¹⁶, Anna Bordas PhD¹⁷, Alexis Sentis PhD¹⁷, Jordi Aceiton BSc¹⁸, Jordi Casabona PhD¹⁷, Carlos Herrero MD⁵¹, Isabel Casas MD⁵², Nathalia Joaqui MD⁵³, Vanessa Laveglia MD⁵³, Grisel Vilagrasa MD⁵⁴, Maria Méndez MD⁵⁵, Laura Minguell MD⁵⁶, Núria Visa MD⁵⁶, Fernando Paredes MD⁵⁶, Anna Vidal-Moreso MD⁵⁷, Rosario Díez MD⁵⁷, Ana Moreira MSc⁵⁸, Evelyn Berbel MD⁵⁸, Stephan Schneider MD⁴, Maria Milà MD⁵⁹, Ana Maldonado MD⁶⁰, Imma Caubet MD⁶¹, Magda Campins PhD⁶², Juliana Esperalba MD⁶³, Andrés Anton PhD⁶³, Jordi Gómez i Prat PhD⁶², Raisa Morales MD⁶², José Santos MD⁶², Pilar Gussinyé MD⁶⁴, Teresa Fenollosa MD⁶⁵, Coral Moreno MD², Joan Azemar MD², Xavier Duran MD⁶⁶, Gemma Terrer MD⁶⁷, Evaristo Galdeano MD⁶⁸, Raquel Plasencia MD⁶⁹, Rebecca Oglesby MD²⁶, Isabel Vives-Oñós PhD⁷⁰, Silvia Sabaté MD², Vanessa Fernandez MD², Cintia Ago MD², Anna Castan MD⁷¹, Francesc Fornaguera MD⁷², Dolors Panadés MD⁷³, Ernesto Mónaco MD⁷⁴, Gemma Ricós MD⁷⁵, Gina Catasús MD⁷⁵, Maria Mendoza MD²⁴, Lidia Busquets MD²⁴, Esperança Macià MD²³, Sandra Segura MD⁷⁶, Ramona Martín MD⁷⁷, Verónica Sandra López MD⁷⁸.

1. Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
2. Equip Pediatria Territorial Alt Penedès-Garraf, Barcelona, Spain.
3. ABS Les Borges Blanques, Lleida, Spain.
4. Hospital d'Olot i Equip Pediàtric Territorial Garrotxa i Ripollès (EPTGiR), Girona, Spain.
5. EAP Figueres, Alt Empordà, Girona, Spain.
6. Hospital Althaia Manresa, Barcelona, Spain.
7. Hospital Universitari del Mar, Barcelona, Spain.
8. EAP Ripollet, Barcelona, Spain.
9. Equip Territorial Pediàtric Sabadell Nord, Barcelona, Spain.

10. EAP Vic Nord, Barcelona, Spain.
11. Hospital Universitari San Joan de Reus, Tarragona, Spain.
12. Hospital Universitari de Vic, Barcelona, Spain.
13. CAP Les Hortes, Barcelona, Spain.
14. EAP Horta, Barcelona, Spain.
15. Hospital Universitari Parc Taulí, Sabadell, Barcelona, Spain.
16. Agència de Qualitat i Avaluació Sanitària de Catalunya, AQuAS, Generalitat de Catalunya, Barcelona, Spain.
17. Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Departament de Salut, Generalitat de Catalunya, Badalona, Spain.
18. Institut d'Investigació Germans Trias i Pujol (IGTP), Badalona, Spain.
19. CIBER Epidemiologia y Salud Pública (CIBERESP), Spain.
20. CAP Cambrils, Tarragona, Spain.
21. CAP Montblanc, Tarragona, Spain.
22. CAP Llibertat Reus, Tarragona, Spain.
23. EAP Manlleu, Barcelona, Spain.
24. EBA Vic Sud, CAP el Remei, Barcelona, Spain.
25. Corporació del Maresme i la Selva, Barcelona, Spain.
26. Pediatria dels Pirineus SCCLP, Lleida, Spain.
27. Consorci Sanitari de Terrassa, Barcelona, Spain.
28. Hospital Comarcal i Atenció Primària del Vendrell i Camp de Tarragona, Tarragona, Spain.
29. EAP Salt, Girona, Spain.
30. Pius Hospital de Valls, Tarragona, Spain.
31. ABS Pla d'Urgell (Mollerussa), Lleida, Spain.
32. Hospital General de Granollers, Barcelona, Spain.
33. Hospital de Nens de Barcelona, Barcelona, Spain.
34. EAP Terres de l'Ebre, Tarragona, Spain.
35. Hospital Universitari Joan XXIII, Tarragona, Spain.
36. CAP Can Serra Hospitalet de Llobregat, Barcelona, Spain.
37. Hospital Universitari Josep Trueta, Girona, Spain.
38. Hospital de Santa Caterina, Salt, Girona, Spain.
39. CAP Almacelles, Lleida, Spain.
40. CAP Poblenou, Barcelona, Spain.
41. EAP Igualada Nord, Hospital Universitari d'Igualada, Barcelona, Spain.
42. CAP Onze de Setembre, Lleida, Spain.
43. Hospital de Palamós, Serveis de Salut Integrats del Baix Empordà, Girona, Spain.
44. Atenció Primària i Hospital Universitari Mútua de Terrassa, Barcelona, Spain.
45. Hospital Universitari Mútua de Terrassa, Barcelona, Spain.
46. ABS Eixample, Lleida, Spain.
47. ABS Bordeta-Magraners, Lleida, Spain.
48. Fundació Salut Empordà, Girona, Spain.
49. CAP Barberà del Vallés, Barcelona, Spain.
50. EAP Baix Berguedà, Barcelona, Spain.
51. Hospital de Barcelona, Barcelona, Spain.
52. Hospital CIMA, Barcelona, Spain.
53. Hospital Universitari General de Catalunya, Barcelona, Spain.

54. Hospital Universitari Dexeus, Barcelona, Spain.
55. Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
56. Hospital Universitari Arnau de Vilanova, Lleida, Spain.
57. Consorci Sanitari del Maresme, Hospital de Mataró, Barcelona, Spain.
58. Fundació Hospital Sant Joan de Déu de Martorell, Barcelona, Spain.
59. Hospital Sagrat Cor i Hospital Quirón Salud del Vallès, Barcelona, Spain.
60. CM Teknon, Barcelona, Spain.
61. Hospital Vall D'Aran, Lleida, Spain.
62. Department of Preventive Medicine and Epidemiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
63. Department of Microbiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
64. Hospital de Mollet, Barcelona, Spain.
65. Gran Sol Badalona, Badalona, Spain.
66. ABS Girona 2 – EAP Can Gibert del Pla, Girona, Spain.
67. ABS Balàfia-Pardinyes, Lleida, Spain.
68. ABS Cappont, Lleida, Spain.
69. ABS Rural Sud-Granadella, Lleida, Spain.
70. Hospital Quironsalud Barcelona, Spain.
71. ABS Bellpuig, Lleida, Spain.
72. CAP La Garriga, Barcelona, Spain.
73. ABS Montornés-Montmeló, Barcelona, Spain.
74. Consorci Sanitari Alt Penedès-Garraf, Barcelona, Spain.
75. CAP Drassanes, Barcelona, Spain.
76. CAP Montroig, Tarragona, Spain.
77. CAP Marià Fortuny Reus, Tarragona, Spain.
78. CAP Centre Hospitalet Llobregat, Barcelona, Spain.

Corresponding author: Antoni Soriano-Arandes, Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Passeig de la Vall d'Hebron, 119-129, 08035 Barcelona, Catalonia, Spain, Tel. +34 93 489 3140/+34 639712438. Email: tsorianoarandes@gmail.com / asoriano@vhebron.net

Summary: We included 1040 COVID-19 patients <16 years, more than 70% were secondary to an adult, whereas 7.7% were index cases. The secondary attack rate was significantly lower in households with COVID-19 pediatric index cases when compared to adults ($p=0.006$).

Abstract

Background

The role of children in household transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains uncertain. Here, we describe the epidemiological and clinical characteristics of children with COVID-19 in Catalonia (Spain) and investigate the dynamics of household transmission.

Methods

Prospective, observational, multicenter study performed during summer and school periods (1 July-31 October, 2020), in which epidemiological and clinical features, and viral transmission dynamics were analyzed in COVID-19 patients <16 years. A pediatric index case was established when a child was the first individual infected within a household. Secondary cases were defined when another household member tested positive for SARS-CoV-2 before the child. The secondary attack rate (SAR) was calculated, and logistic regression was used to assess associations between transmission risk factors and SARS-CoV-2 infections.

Results

The study included 1040 COVID-19 patients <16 years. Almost half (47.2%) were asymptomatic, 10.8% had comorbidities, and 2.6% required hospitalization. No deaths were reported. Viral transmission was common among household members (62.3%). More than 70% (756/1040) of pediatric cases were secondary to an adult, whereas 7.7% (80/1040) were index cases. The SAR was significantly lower in households with COVID-19 pediatric index cases during the school period relative to summer ($p=0.02$), and when compared to adults ($p=0.006$). No individual or environmental risk factors associated with the SAR were identified.

Conclusions

Children are unlikely to cause household COVID-19 clusters or be major drivers of the pandemic even if attending school. Interventions aimed at children are expected to have a small impact on reducing SARS-CoV-2 transmission.

Keywords: coronavirus; SARS-CoV-2; child; household; transmission.

Accepted Manuscript

Introduction

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a global public health crisis. It is essential to understand the dynamics of SARS-CoV-2 transmission to plan effective infection control, and spread of the virus within households is known to be high.¹⁻³ The precise role of children in transmitting this novel coronavirus is uncertain, but it is now evident that strict measures to control the pandemic can be detrimental to a child's health and well-being.⁴

Children seem to be largely spared from the direct health effects of COVID-19. Generally they have milder disease⁵ and may be less susceptible to infection.^{6,7} Data from several countries^{5,8} have shown that children do not amplify transmission within households, schools, or the community^{9,10}. However, these studies were mainly performed during the first wave of the coronavirus disease 2019 (COVID-19) pandemic, when strict lockdown measures including school closure were adopted by most countries; hence, the results could somehow be biased.¹¹⁻¹⁴ One such example is our retrospective pilot study of all COVID-19 pediatric cases in Catalonia (Spain) that occurred during the first lockdown (10 March-31 May, 2020).¹⁵ We found that children played a small role in viral transmission among household members, but these results should be confirmed in a prospective design.

A much larger percentage of children than adults with COVID-19 are asymptomatic, and this has been proposed as a reason for their minor role in viral shedding. In a study from Wuhan (China), no secondary infections were detected among 1174 close contacts with asymptomatic pediatric cases.¹⁶ Nonetheless, studies based on SARS-CoV-2 viral load in respiratory samples suggest that children could potentially transmit the virus in the same way as adults, even when asymptomatic.^{17,18} Therefore, more data are needed to better

define the contribution of children to SARS-CoV-2 transmission, so that an appropriate course of action can be designed for this age group.

On 13 March 2020, 5492 Catalan schools with 1,565,478 students were closed in an effort to contain the spread of COVID-19.¹⁹ Soon after, the “COVID-19 Pediatric Disease in Catalonia” (COPEDI-CAT) project was launched to assess the contribution of children to transmitting the virus. In this study, our aim was to describe the epidemiological and clinical characteristics of pediatric COVID-19 cases in Catalonia and investigate the dynamics and potential role of children in household transmission during the summer break and after school initiation.

Methods

Study design

This is a prospective, observational, multicenter study. Between 1 July and 31 October, 2020, data were collected from COVID-19 patients <16 years of age. Patients were diagnosed in the participating centers by reverse transcription polymerase chain reaction (RT-PCR) or rapid antigen testing (PANBIO COVID-19 Ag rapid test device, Abbott). In the primary care setting in Catalonia, children are followed by a pediatrician up to the age of 16 years; hence, this age was set as the upper limit for inclusion. We followed the STROBE statement for observational studies.²⁰ Two study periods were established, *summer time* (1 July-15 September) and *school time* (16 September-31 October), based on the markedly different epidemiological background before and after schools reopened. Nonpharmaceutical interventions were applied in all schools, including face masks in classrooms and school buildings in children older than 6 years.

Data sources and setting

Catalonia, an autonomous region in northeast Spain with 7.5 million inhabitants (1,581,341 younger than 20 years), has a universal, publicly-funded health system with 7 sub-regional departments and more than 400 primary health care centers.

Within the COPEDI-CAT project, more than 120 pediatricians from 71 primary health centers and public and private hospitals recorded the demographic, epidemiologic, clinical, and diagnostic data of pediatric COVID-19 cases. Information on the total and positive SARS-CoV-2 RT-PCR results related to eligible participants was delivered by the Catalan Agency for Quality and Health Assessment (AQuAS), which obtained the data from the Catalan Epidemiological Surveillance Network and the referral microbiological laboratories.²¹

A questionnaire was designed and distributed to all participating pediatricians to collect clinical and microbiological information related to pediatric COVID-19 cases and their household contacts (**Supplemental data**).

Study definitions

A confirmed COVID-19 case was defined as any individual testing SARS-CoV-2 positive by real-time RT-PCR or by antigen testing in a respiratory specimen. Viral antigen testing was only available during the last week of the study period (26-31 October, 2020). To avoid selection bias in case recruitment, pediatricians recorded all positive cases seen in daily practice. However, during work overload peaks, they only collected data from the first 5 positive cases per day. Contact tracing for each COVID-19 patient <16 years was done by the COPEDI-CAT group. Household contacts were defined as all persons living in the same household as the first patient diagnosed, regardless of the duration or proximity of the contact. Follow-up was performed by the patient's pediatrician during a primary care visit, or by telephone interview with parents or legal guardians, using the dedicated

questionnaire. All data were recorded in a web-based platform, Research Electronic Data Capture (REDCap®) database.

A pediatric index case was established when a child was the first infected member in the household. The chronology of symptoms and the SARS-CoV-2 RT-PCR test date in contacts were considered surrogates that would reflect transmission dynamics. A secondary case was defined as a symptomatic household contact testing RT-PCR-positive for SARS-CoV-2 before the child. A primary case was established when no household contacts tested SARS-CoV-2 RT-PCR-positive other than the child or when infection temporality could not be established in positive contacts. In asymptomatic patients, onset was defined as the date of specimen collection for the first positive RT-PCR.

Statistical analysis

A descriptive analysis was performed in pediatric and adult cases identified during the two study periods. Bivariate tests (chi-square and independent sample t tests) were used to assess differences in sociodemographic, household, and clinical characteristics between summer and school periods in index and secondary cases. The secondary attack rate (SAR) was calculated by dividing the total number of household contacts by the number of new SARS-CoV-2 infections among contacts. Univariate and multivariate logistic regression analyses were used to assess associations between transmission risk factors and SARS-CoV-2 infection in pediatric and adult index cases. For the multivariate generalized regression analysis, we selected variables representative of different potential modes of SARS-CoV-2 transmission, those that had a greater effect size on univariate analysis, and those that were significant ($p < 0.05$). All models were adjusted for sex, age, number of household contacts, and whether or not index cases were symptomatic.

Ethical considerations

Ethical approval was obtained from the referral IDIAP-J. Gol Research Foundation for Primary Care in Catalonia, Spain (20/187-PCV), and the coordinating center of the study, Vall d'Hebron Research Institute, Barcelona, Spain (PR(AG)475/2020).

Results

In the overall study period, 26,665 of 417,578 (6.4%) SARS-CoV-2 RT-PCRs in individuals younger than 16 years tested positive.

We initially recruited 1309/26,665 (4.9%) COVID-19 pediatric patients. Ultimately, 1040 patients aged <16 years with complete clinical, epidemiological, and microbiological data were included (**Figure 1**): 547 during summer (1 July-15 September) and 493 after schools reopened (16 September-31 October). The clinical and epidemiological data (**Table 1**) showed no significant differences in sex, but both study periods had a higher percentage of patients aged 6 to 12 years (358/1040, 34.4%). The analysis found a median [IQR] of 3 [2-4] household contacts, a living area of 90 [70-110] m² with 3 [3-4] rooms, and smokers in 20.8% (197/947) of households (**Table 1**).

Nearly half the pediatric cases (491/1040; 47.2%) were asymptomatic, with a higher rate during the school than summer period (51.7% vs 43.1%; $p=0.006$). Most symptomatic cases (549/1040; 52.8%) had mild symptoms (**Table 2**). Overall, 10.8% (111/1028, information missing in 12) had some type of comorbidity, 27 children (2.6%) required hospitalization, there were no deaths, and 6 children had mainly minor sequelae: persistent fever (2), anosmia, ageusia, aphonia, and prolonged positive RT-PCR together with mesenteric lymphadenitis. Pediatric index cases were more commonly symptomatic than secondary cases (83.7% vs 47.1%; $p<0.001$) during both periods (**Table 3**). Differences in median number of household contacts between index and secondary cases were attributable to the different ranges in the two groups. Otherwise, no differences regarding sex, age

range, living area (m²), presence of smokers in the household, or hospitalization requirement were found between index and secondary cases. Of note, only 5 children with comorbidities (3 preterm babies, 1 neurological abnormality, and 1 sickle cell disease and cancer) were hospitalized. There were no differences regarding the presence of symptoms or hospitalization requirement between these patients and children without comorbidities.

According to the pediatric COVID-19 case classification used, 72.7% (756/1040) of children were cases secondary to an adult case, and 5.0% (52/1040) were secondary to another child. Only 7.7% (80/1040) of children included were household index cases. The remaining 14.6% (152/1040) were primary cases; 109 (71.7%) did not transmitted the infection to any of the household contacts, and we were unable to determine the directionality of the transmission in 43 (28.3%) of them. Even when schools were open, pediatric cases were much more likely to be secondary cases from household transmission rather than index cases (**Table 3**).

In total, 3392 household contacts were linked to the 1040 pediatric cases. Epidemiologic and clinical features are shown in **Table 4**. Age, family member relationships, and percentage of positive SARS-CoV-2 RT-PCRs per household according to age of the pediatric case differed significantly between summer and school periods. The median [IQR] of SARS-CoV-2 infections per household was 62.3% [33.3%-100.0%] with no differences between the periods. The SAR for SARS-CoV-2 infection was significantly lower in households with pediatric index cases than those with adult index cases (59.0% vs 67.6%; $p=0.006$) (**Figure 2 and Table 5**). No individual or environmental risk factors for an increased SAR were detected in pediatric index cases. Of note, the SAR was significantly lower during the school period in this group (53.0% vs 64.4%; $p=0.02$). When index case was younger than 3 years of age, SAR was significantly lower during the school period than in summer time (62.1% vs 33.3%; $p=0.02$). We did not find any other significant differences between school and summer time for other age-group index cases. When the index case was an adult, the SAR was significantly higher among female or non-adult household contacts, and when family size was ≤ 4 members (**Table 5**). In

households with an adult index, the SAR was almost identical in the summer and school periods, (67.7% vs 67.5%, respectively).

Among the 80 pediatric index cases, 14 of them did not transmit the infection to any of the household contacts. On the contrary, among adult index cases, all of them infected at least someone else at home.

Discussion

The contribution of children to spreading SARS-CoV-2 has been debated since early days of the pandemic. In this study, we assessed the clinical and epidemiological characteristics, and determined viral transmission dynamics of 1040 pediatric COVID-19 cases linked to 3392 household contacts.

Most children <16 years had mild disease: nearly half were asymptomatic (47.2%) and very few needed hospital admission (2.6%). Children were tested as a part of the contact tracing studies within the household but also due to mass screening studies performed in the schools. In fact, asymptomatic cases were higher when the schools were open (51.7%) than in summer time (43.1%) ($p=0.006$) likely as a result of these mass screening studies (**Table 2**). Within their households, most pediatric COVID-19 cases were secondary to an adult case (72.7%), and most importantly, only 7.7% of children were drivers of SARS-CoV-2 infection. COVID-19 disease spreads easily among household members; 6 of every 10 contacts tested RT-PCR positive, but very few (2.4%) required hospitalization. The SAR was significantly lower in households where children rather than adults had transmitted SARS-CoV-2 ($p=0.006$), and it was even lower during the school period, when children were expected to be more contagious because of social interaction with classmates.

The household SAR we found (62.3%) is significantly higher than values reported in studies from China (11.2%),²² Korea (11.8%),² and the United States (29.0%),²³ but it is within the range found in

two meta-analyses (4.6% to 90%).^{24,25} On stratification by age in available household studies, children were seldom the index cases (4%-8%),^{11,26} a finding similar to our results (7.7%), but higher than a recent published study performed in the first wave²⁷. These differences may be due to different epidemiological scenarios, with a very limited childhood interactions in stronger lockdowns.

A recent systematic review concluded that children and adolescents are less susceptible to SARS-CoV-2 infection than adults, with the lowest risk in the 10 to 14 year-old group.⁶ However, in the present study, the SAR was significantly higher in transmission from adult index cases to child household contacts than from adults to adult contacts ($p < 0.001$). This discordant finding may be attributable to the study focus on pediatric cases, with possible underestimation of the adulthood SAR.

In contrast to previous assumptions that asymptomatic COVID-19 in children is associated with silent transmission¹⁷ or that asymptomatic index cases are associated with a lower SAR,^{1,16} we found no differences in the SAR between symptomatic and asymptomatic index cases either in children or adults, even though nearly half the children included were asymptomatic. Asymptomatic pediatric cases were significantly higher during the school than summer period, likely because of generalized screening performed in schools ($p = 0.006$).

Regarding the clinical features of COVID-19, the most common symptoms described in European adults have been headache (70.3%), loss of smell (70.2%), and nasal obstruction (67.8%),²⁸ which contrasts with the fever (58.3%), cough (47.3%) and sore throat (18.3%) in children²⁹ (similar to our data). As reported, few affected children have an underlying pathology (14%-25%, mainly chronic lung disease and cardiovascular disease),^{15,29,30} and only 2.5%-4.1% require hospitalization.³⁰ Again, our data support these findings: few children had comorbidities and there were no differences regarding symptoms and hospitalization rates between those with and without comorbidities. These

data reinforce the idea that no special SARS-CoV-2 preventive measures are needed for children with underlying diseases.

Overcrowding appears to be determinant in SARS-CoV2 dissemination,³¹ but the risk of secondary cases was not higher in households with a larger number of members or smaller living area. Socioeconomic status was not recorded here; further research is needed to address the effect of poverty on pediatric SARS-CoV2 transmission.

In Catalonia, schools were closed on 13 March, two days after the pandemic was officially declared, to decrease SARS-CoV2 community transmission.¹⁹ Most schools did not reopen until September, 2020. During the summer, some sectors of our society discussed whether closing schools was the right decision, as data were emerging of low transmissibility in children.^{32,33} Some countries such as Taiwan were able to minimize SARS-CoV2 spread without complete school closure.³⁴ COVID-19 modeling studies have predicted that school closure alone would prevent 2%-4% of deaths, a rate far from that achieved with other social distancing interventions.³⁵ Nonetheless, other studies investigating nonpharmaceutical interventions to reduce COVID-19 highlight school closure as a major option to consider.^{36,37} However, this radical measure can have adverse consequences³⁸. Closing schools interrupts learning and can lead to poor nutrition, stress, and social isolation in children.³⁶ Disruption of education has a significant negative impact on society as a whole and on children's health and well-being, potentially leading to inequity issues and a loss of years of life.⁴

Official data from the three months after school reopening in Catalonia are reassuring, as viral transmission was low in schoolmates and teachers.³⁹ Our data confirm a milder disease course in children and show that their contribution to transmission is low during the school period even in the high-risk household environment, where (in contrast to the norm in schools) no preventive measures are adopted. These findings support the safety of maintaining schools open, as proposed

by the European Centre for Disease Prevention and Control⁴⁰ and the American Academy of Pediatrics in its last interim report on 5 January, 2021.⁴¹

The prospective design, large sample, and collaborative network of pediatricians from primary health centers and hospitals add value to this study. These physicians, who recorded household cases and contact data, knew all the families included; hence, the final case classification is likely more accurate than if it had been done by external researchers.

Nonetheless, the study has limitations. First, numerous pediatricians within COPEDI-CAT registered the data simultaneously, and even with standardized recording, data entry errors can occur. We addressed this issue by ongoing double-checking, and deep review of all data before analysis. Second, information on older children was limited, as primary care pediatricians only attend children aged <16 years. Adolescents 16 to 18 years, who may have a major role in viral transmission, were not included. Third, the index case in each cluster was defined as the person in the household who first developed symptoms or first tested RT-PCR SARS-CoV-2 positive. Therefore, the contribution of asymptomatic individuals to transmission may have been underestimated. And finally, these findings are specific to the variant distribution at the time of the study, and could be different if the new SARS-CoV-2 variants shift their distribution in the future.

Conclusions

SARS-CoV-2 transmission is high among household members, but most children and young adolescents are mildly affected. Our results show that children, whether symptomatic or not, do not greatly contribute to household clusters of infection and are unlikely to be major drivers of the pandemic even when schools are open. Interventions aimed at children are expected to have a small impact on reducing COVID-19 and should be optimized to exclude overly stringent measures that can profoundly affect the well-being of this population.

NOTES

Acknowledgments

This study was carried out using anonymized data provided by the Catalan Agency for Quality and Health Assessment (AQuAS) within the framework of the PADRIS Program. We are very grateful to the affected individuals and their families who participated in this study. We thank Celine Cavallo for English language support and Yesika Díaz for carrying out the statistical analysis. We also thank the Catalanian Pediatrics Society for their support.

Finally, we want to thank Ms. Ingrid Carbonés, Ms. Eva del Amo, Ms. Saida Rídao, Ms. Montserrat García, Ms. Jenifer Davila and Ms. Cristina Montiel for their collaboration in data collection in the pilot study performed during the lockdown.

Funding information: This study did not receive specific funding.

Potential conflicts of interest: P.S-P. reports grants and personal fees from Gilead SL and CSL Behring, and grants from Grifols SA, outside the submitted work. All other authors of this study have no potential conflicts of interest to disclose regarding the work of the manuscript.

References

1. Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. *BMJ* 2020;371:m3862. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33097561>
2. Park YJ, Choe YJ, Park O, et al. Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020. *Emerg Infect Dis* 2020;26(10):2465–8. Available from: http://wwwnc.cdc.gov/eid/article/26/10/20-1315_article.htm
3. Lei H, Xu X, Xiao S, Wu X, Shu Y. Household transmission of COVID-19—a systematic review and meta-analysis. *J Infect* 2020; Available from: <https://doi.org/10.1016/j.jinf.2020.08.033>
4. Christakis DA, Van Cleve W, Zimmerman FJ. Estimation of US Children’s Educational Attainment and Years of Life Lost Associated With Primary School Closures During the Coronavirus Disease 2019 Pandemic. *JAMA Netw open* 2020 [cited 2020 Nov 16];3(11):e2028786. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33180132>
5. Davies NG, Klepac P, Liu Y, Prem K, Jit M, Eggo RM. Age-dependent effects in the transmission and control of COVID-19 epidemics. *Nat Med* 2020;26(8):1205–11. Available from: <http://www.nature.com/articles/s41591-020-0962-9>
6. Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 Infection among Children and Adolescents Compared with Adults: A Systematic Review and Meta-analysis. *JAMA Pediatr* 2020;1–14.
7. Brotons P, Launes C, Buetas E, et al. Susceptibility to Sars-COV-2 Infection Among Children And Adults: A Seroprevalence Study of Family Households in the Barcelona Metropolitan Region, Spain. *Clin Infect Dis*. 2020 Nov 12:ciaa1721. doi: 10.1093/cid/ciaa1721. Epub ahead of print.
8. Munro APS, Faust SN. COVID-19 in children: current evidence and key questions. *Curr Opin*

- Infect Dis 2020 [cited 2020 Dec 31];33(6):540–7. Available from:
<https://journals.lww.com/10.1097/QCO.0000000000000690>
9. Buonsenso D, De Rose C, Moroni R, Valentini P. SARS-CoV-2 Infections in Italian Schools: Preliminary Findings After 1 Month of School Opening During the Second Wave of the Pandemic. *Front Pediatr*. 2021 Jan 14;8:615894. doi: 10.3389/fped.2020.615894.
 10. Tönshoff B, Müller B, Elling R, et al. Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany. *JAMA Pediatr*. 2021 Jan 22:e210001. doi: 10.1001/jamapediatrics.2021.0001. Epub ahead of print.
 11. Posfay-Barbe KM, Wagner N, Gauthey M, et al. COVID-19 in Children and the Dynamics of Infection in Families. *Pediatrics* 2020;146(2):e20201576. Available from:
<http://pediatrics.aappublications.org/lookup/doi/10.1542/peds.2020-1576>
 12. Somekh E, Gleyzer A, Heller E, et al. The role of children in the dynamics of intra family coronavirus 2019 spread in densely populated area. *Pediatr Infect Dis J* 2020;39(8):E202–4. Available from:
https://journals.lww.com/pidj/Fulltext/2020/08000/The_Role_of_Children_in_the_Dynamics_of_Intra.30.aspx
 13. Heavey L, Casey G, Kelly C, Kelly D, McDarby G. No evidence of secondary transmission of COVID-19 from children attending school in Ireland, 2020. *Eurosurveillance* 2020;25(21):1–4.
 14. Macartney K, Quinn HE, Pillsbury AJ, et al. Transmission of SARS-CoV-2 in Australian educational settings: a prospective cohort study. *Lancet Child Adolesc Heal* 2020;4(20):807–16. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S2352464220302510>
 15. Soriano-Arandes A, Ferran B, Campins M, et al. Potential role of children in the household transmission of SARS-CoV-2 infection in Catalonia (Spain). 2020;639712438(October):1–9. Available from: www.preprints.org

16. Cao S, Gan Y, Wang C, et al. Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China. *Nat Commun* 2020;11(1):1–7. Available from: <http://dx.doi.org/10.1038/s41467-020-19802-w>
17. Han MS, Choi EH, Chang SH, et al. Clinical Characteristics and Viral RNA Detection in Children with Coronavirus Disease 2019 in the Republic of Korea. *JAMA Pediatr* 2020;03080:1–8.
18. Heald-Sargent T, Muller WJ, Zheng X, Rippe J, Patel AB, Kocielek LK. Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19). *JAMA Pediatr* 2020;174(9):902. Available from: <https://jamanetwork.com/journals/jamapediatrics/fullarticle/2768952>
19. Departament de Salut - Generalitat de Catalunya. RESOLUCIÓ SLT/737/2020. Barcelona: Disposicions; 2020 [cited 2020 Dec 31]. Available from: <https://www.gencat.cat/dogc>
20. Vandembroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. *Int J Surg* 2014;12(12):1500–24. Available from: <http://dx.doi.org/10.1016/j.ijsu.2014.07.014>
21. Agència de Qualitat i Avaluació Sanitàries de Catalunya. Dades Coronavirus AQUAS. <https://aquas.gencat.cat/ca/actualitat/ultimes-dades-coronavirus/>
22. Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet Infect Dis* 2020;20(8):911–9.
23. Lewis NM, Chu VT, Ye D, et al. Household Transmission of SARS-CoV-2 in the United States. *Clin Infect Dis* 2020 [cited 2020 Dec 31]; Available from: <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1166/5893024>
24. Koh WC, Naing L, Chaw L, et al. What do we know about SARS-CoV-2 transmission? A

- systematic review and meta-analysis of the secondary attack rate and associated risk factors. *PLoS One* 2020;15(10):1–23. Available from: <http://dx.doi.org/10.1371/journal.pone.0240205>
25. Madewell ZJ, Yang Y, Longini Jr IM, et al. Household Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis. *JAMA Netw Open* 2020;3(12):e2031756–e2031756. Available from: <http://dx.doi.org/10.1371/journal.pone.0240205>
26. Zhu Y et al. A meta-analysis on the role of children in SARS-CoV-2 in household transmission clusters. *Clin Infect Dis* 2020; Available from: 10.1093/cid/ciaa1825
27. Buonsenso D, Valentini P, De Rose C, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposure to adults with COVID-19: Preliminary findings. *Pediatr Pulmonol.* 2021 Jan 20. doi: 10.1002/ppul.25280. Epub ahead of print.
28. European Centre for Disease Prevention and Control. Clinical characteristics of COVID-19. 2020 [cited 2020 Dec 31]; Available from: <https://www.ecdc.europa.eu/en/covid-19/latest-evidence/clinical>
29. Escosa-García L, Aguilera-Alonso D, Calvo C, Mellado MJ, Baquero-Artigao F. Ten key points about COVID-19 in children: The shadows on the wall. *Pediatr Pulmonol.* 2020 Oct;55(10):2576–2586. doi: 10.1002/ppul.25025. Epub 2020 Aug 22.
30. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020. *MMWR Morb Mortal Wkly Rep* 2020 [cited 2020 Dec 31];69(24):759–65. Available from: http://www.cdc.gov/mmwr/volumes/69/wr/mm6924e2.htm?s_cid=mm6924e2_w
31. De Ver Dye T, Muir E, Farovitch L, Siddiqi S, Sharma S. Critical medical ecology and SARS-COV-2 in the urban environment: a pragmatic, dynamic approach to explaining and planning for research and practice. *Infect Dis Poverty* 2020;9(1):71. Available from: <https://idpjournal.biomedcentral.com/articles/10.1186/s40249-020-00694-3>

32. Li W, Zhang B, Lu J, et al. Characteristics of Household Transmission of COVID-19. *Clin Infect Dis* 2020 [cited 2020 Dec 31];71(8):1943–6. Available from: <https://academic.oup.com/cid/article/71/8/1943/5821281>
33. Esposito S, Principi N. School Closure During the Coronavirus Disease 2019 (COVID-19) Pandemic. *JAMA Pediatr* 2020;174(10):921. Available from: <https://jamanetwork.com/journals/jamapediatrics/fullarticle/2766114>
34. Wang CJ, Ng CY, Brook RH. Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing. *JAMA - J. Am. Med. Assoc.* 2020 [cited 2020 Dec 31];323(14):1341–2. Available from: <https://pubmed.ncbi.nlm.nih.gov/32125371/>
35. Ferguson NM, Laydon D, Nedjati-Gilani G, et al. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. London: 2020 [cited 2020 Dec 31]. Available from: <https://doi.org/10.25561/77482>.
36. Haug N, Geyrhofer L, Londei A, et al. Ranking the effectiveness of worldwide COVID-19 government interventions. *Nat Hum Behav* 2020;4(December). Available from: <http://dx.doi.org/10.1038/s41562-020-01009-0>
37. Li Y, Campbell H, Kulkarni D, et al. The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries. *Lancet Infect Dis* 2020; Available from: [http://dx.doi.org/10.1016/S1473-3099\(20\)30785-4](http://dx.doi.org/10.1016/S1473-3099(20)30785-4)
38. Buonsenso D, Roland D, De Rose C, et al. SCHOOLS CLOSURES DURING THE COVID-19 PANDEMIC: A Catastrophic Global Situation. *Pediatr Infect Dis J.* 2021 Jan 12. doi: 10.1097/INF.0000000000003052. Epub ahead of print.
39. Departament Educació. Generalitat de Catalunya. 2020; Available from: <http://educacio.gencat.cat/es/actualitat/escolasegura/tracacovid/dades-covid19-centres/#/>

40. European Centre for Disease Prevention and Control. COVID-19 in children and the role of school settings in COVID-19 transmission. 2020 (December 23, 2020). Available from: <https://www.ecdc.europa.eu/en/publications-data/children-and-school-settings-covid-19-transmission#no-link>
41. Editor NC. AAP continues to advocate measures to allow students to return safely to school. 2021; Available from: <https://www.aapublications.org/news/2021/01/05/covid-school-safety-010521>

Accepted Manuscript

Table 1. Main clinical and epidemiological data of study participants by study period

| | Total, n=1040 | | Summer period, n=547 | | School period, n=493 | |
|------------------------------------|------------------|--------|-------------------------|--------|-------------------------|--------|
| | median, n | IQR, % | median, n | IQR, % | median, n | IQR, % |
| Sex | | | | | | |
| Male | 529 | 50.9 | 278 | 50.8 | 251 | 50.9 |
| Female | 511 | 49.1 | 269 | 49.2 | 242 | 49.1 |
| Age, y | | | | | | |
| 0 to <3 | 223 | 21.4 | 136 | 24.9 | 87 | 17.7 |
| 3 to <6 | 181 | 17.4 | 106 | 19.4 | 75 | 15.2 |
| 6 to <12 | 358 | 34.4 | 174 | 31.8 | 184 | 37.3 |
| 12 to <16 | 278 | 26.7 | 131 | 23.9 | 147 | 29.8 |
| Household contacts | 3 | 2-4 | 3 | 2-4 | 3 | 2-4 |
| Living area (m²) | 90 | 70-110 | 90 | 75-110 | 90 | 70-110 |
| Rooms, n | 3 | 3-4 | 3 | 3-4 | 3 | 3-4 |
| Smokers in household, yes | 197 | 18.9 | 109 | 19.9 | 88 | 17.8 |
| Symptoms,* yes | 549 | 52.8 | 311 | 56.9 | 238 | 48.3 |
| Admitted to hospital, yes | 27 | 2.6 | 17 | 3.1 | 10 | 2.0 |
| Final outcome | | | | | | |
| Sequelae | 6 | 0.6 | 4 | 0.7 | 2 | 0.4 |
| Comorbidities, yes | 111 | 10.7 | 52 | 9.5 | 59 | 12.0 |
| Case classification | | | | | | |
| Index | | | | | | |
| Primary | 80 | 7.7 | 39 | 7.1 | 41 | 8.3 |
| Secondary to adult | 152 | 14.6 | 73 | 13.3 | 79 | 16.0 |
| Secondary to another child | 756 | 72.7 | 414 | 75.7 | 342 | 69.4 |
| Unclassified | 52 | 5.0 | 21 | 3.8 | 31 | 6.3 |

*p-value for symptoms was significantly different (0.006) between summer and school periods

Table 2. Clinical features of patients by study period

| Signs and symptoms in children with COVID-19 (1 July to 31 October, 2020) | | | | |
|---|--------------|---------------|---------------|--------------|
| | Total | Summer period | School period | p-value |
| | N=1040 | N=547 | N=493 | |
| Signs/symptoms | N (%) | N (%) | N (%) | |
| Asymptomatic | 491 (47.2%) | 236 (43.1%) | 255 (51.7%) | 0.006 |
| Symptomatic | 549 (52.8%) | 311 (56.9%) | 238 (48.3%) | |
| Fever | 395 (71.9%) | 236 (75.6%) | 159 (66.5%) | 0.017 |
| Cough | 206 (37.4%) | 91 (29.2%) | 115 (48.1%) | <0.001 |
| Headache | 130 (23.6%) | 64 (20.5%) | 66 (27.6%) | 0.073 |
| Fatigue | 128 (23.2%) | 60 (19.2%) | 68 (28.4%) | 0.018 |
| Diarrhea | 91 (16.5%) | 56 (18.0%) | 35 (14.6%) | 0.233 |
| Abdominal pain | 72 (13.1%) | 44 (14.1%) | 28 (5.7%) | 0.277 |
| Vomiting | 53 (9.6%) | 29 (9.3%) | 24 (11.7%) | 0.048 |
| Ageusia/Anosmia | 45 (8.2%) | 28 (9.0%) | 17 (7.1%) | 0.524 |
| Skin lesions | 27 (4.9%) | 19 (6.1%) | 8 (3.3%) | 0.999 |
| Dyspnea | 26 (4.7%) | 9 (2.9%) | 17 (7.1%) | 0.036 |
| Others | 135 (24.5%) | 86 (27.6%) | 49 (20.5%) | 0.071 |

Table 3. Epidemiologic characteristics of pediatric index and secondary cases during the two study periods

| | Total | | Summer period | | School period | |
|---|--------------------------------|-------------------------------------|--------------------------------|-------------------------------------|--------------------------------|-------------------------------------|
| | Index cases (n=80) (n/%) | Secondary cases (n=756) (n/%) | Index cases (n=39) (n/%) | Secondary cases (n=414) (n/%) | Index cases (n=41) (n/%) | Secondary cases (n=342) (n/%) |
| Sex | | | | | | |
| Male | 36/45.0 | 385/50.9 | 19 | 205 | 17 | 180 |
| Female | 44/55.0 | 371/49.1 | 20 | 209 | 24 | 162 |
| Age, y | | | | | | |
| 0 to <3 | 15/18.7 | 155/20.5 | 11/28.2 | 95/23.0 | 4/9.7 | 60/17.5 |
| 3 to <6 | 14/17.5 | 136/18.0 | 7/17.9 | 85/20.5 | 7/17.1 | 51/14.9 |
| 6 to <12 | 27/33.8 | 261/34.5 | 12/30.8 | 132/31.9 | 15/36.6 | 129/37.7 |
| 12 to <16 | 24/30.0 | 204/27.0 | 9/23.1 | 102/24.6 | 15/36.6 | 102/29.8 |
| Household contacts, median/IQR | 3/2-4 | 3/2-4 | 3/3-4.5 | 3/2-4 | 3/2-4 | 3/2-4 |
| Living area, m², median/IQR | 80/70-100 | 90/70-110 | 79/65.3-97.5 | 90/75-110 | 87.5/75-100 | 87/70-110 |
| Rooms, n, median/IQR | 3/3-4 | 3/3-4 | 3/3-3 | 3/3-4 | 3/3-4 | 3/3-4 |
| Smokers in household, yes | 20/25.0 | 139/18.4 | 13/33.3 | 76/18.4 | 7/17.1 | 63/18.4 |
| Symptoms, yes | 67/83.7 | 356/47.1 | 36/92.3 | 204/49.3 | 31/75.6 | 152/44.4 |
| Hospital admission, yes | 4/5.0 | 15/2.0 | 4/10.3 | 8/1.9 | 0/0.0 | 7/2.0 |
| Final outcome | | | | | | |
| Sequelae | 3/3.8 | 3/0.4 | 1/2.6 | 3/0.7 | 2/4.9 | 0/0.0 |
| Comorbidities, yes | 12/15.0 | 71/9.4 | 5/12.8 | 37/8.9 | 7/17.1 | 34/9.9 |

Table 4. Baseline characteristics of household contacts of children with COVID-19

| | Total (n=3392) | | Summer period (n=1766) | | School period (n=1626) | |
|--|-------------------|--------------|---------------------------|--------------|---------------------------|--------------|
| | N | % | n | % | n | % |
| Sex | | | | | | |
| Male | 1641 | 48.4 | 840 | 47.6 | 801 | 49.3 |
| Female | 1750 | 51.6 | 925 | 52.4 | 825 | 50.7 |
| Age, y, median/IQR) | 34 | 13-43 | 34 | 14-43 | 35 | 13-44 |
| Family relationship | | | | | | |
| Father | 837 | 24.7 | 427 | 24.2 | 410 | 25.2 |
| Mother | 961 | 28.3 | 495 | 28.0 | 466 | 28.7 |
| Sister/brother | 1139 | 33.6 | 549 | 31.1 | 590 | 36.3 |
| Grandparents | 158 | 4.6 | 102 | 5.8 | 56 | 3.4 |
| Others | 288 | 8.5 | 188 | 10.6 | 100 | 6.2 |
| Missing | 9 | 0.3 | 5 | 0.3 | 4 | 0.2 |
| Symptoms, yes | 1386 | 40.9 | 773 | 43.8 | 613 | 37.7 |
| Total positive PCRs among household contacts | 2091 | 61.6 | 1100 | 62.3 | 991 | 60.9 |
| Positive PCRs by household, median (IQR) | 62.3 | (33.3-100.0) | 63.5 | (33.3-100.0) | 60.9 | (33.3-100.0) |
| Positive PCRs by household and age of pediatric case, y | | | | | | |
| 0 to <3 | 449 | 21.5 | 269 | 24.4 | 180 | 18.2 |
| 3 to <6 | 395 | 18.9 | 240 | 21.8 | 155 | 15.6 |
| 6 to <12 | 720 | 34.4 | 355 | 32.3 | 365 | 36.8 |
| 12 to <16 | 527 | 25.2 | 236 | 21.5 | 291 | 29.4 |
| Hospital admission, yes | 80 | 2.4 | 48 | 2.7 | 32 | 2.0 |
| ICU admission among hospitalizations, yes | 3 | 3.7 | 1 | 2.1 | 2 | 6.2 |

Table 5. Secondary attack rates and household risk factors for SARS-CoV-2 infection between paediatric and adult index cases

| Pediatric index case | Infected cases, N | Total contacts, N | Secondary attack rates, % | OR (95% CI) | p-value |
|-----------------------------------|-------------------|-------------------|---------------------------|------------------|---------|
| General transmission rate* | 167 | 283 | 59.0 | | |
| Contact sex | | | | | |
| Female | 94 | 150 | 62.7 | 1.71 (0.81-3.59) | 0.16 |
| Male | 73 | 133 | 54.9 | Ref. | - |
| Contact age | | | | | |
| < 18 y | 60 | 100 | 60.0 | Ref. | - |
| ≥ 18 y | 107 | 183 | 58.5 | 0.56 (0.21-1.49) | 0.246 |
| 18-39 y | 49 | 84 | 58.3 | | |
| 40-65 y | 56 | 97 | 57.7 | | |
| ≥ 65 y | 2 | 2 | 100 | | |
| Index case sex | | | | | |
| Female | 89 | 155 | 57.4 | 0.77 (0.39-1.49) | 0.432 |
| Male | 78 | 128 | 60.9 | Ref. | - |
| Pediatric index case age | | | | | |
| 0 to <3 y | 39 | 53 | 73.6 | 2.27 (0.62-8.35) | 0.216 |
| 3 to <6 y | 24 | 47 | 51.1 | 0.88 (0.39-1.98) | 0.75 |
| 6 to <12 y | 59 | 101 | 58.4 | 1.18 (0.53-2.65) | 0.687 |
| 12 to <16 y | 45 | 82 | 54.9 | Ref. | - |
| Index case symptoms | | | | | |
| Yes | 150 | 247 | 60.7 | 1.72 (0.65-4.52) | 0.276 |
| No | 17 | 36 | 47.2 | Ref. | - |
| Family size | | | | | |
| 4 or fewer | 67 | 116 | 57.8 | 0.89 (0.45-1.77) | 0.739 |
| More than 4 | 100 | 167 | 59.9 | Ref. | - |
| Relationship | | | | | |
| | 48 | 76 | 63.2 | Ref. | - |

| Mother | 38 | 65 | 58.5 | 1.44 (0.6-3.47) | 0.418 |
|-----------------------------------|-------------------|-------------------|---------------------------|-------------------------|------------------|
| Father | 62 | 108 | 57.4 | 0.58 (0.2-1.63) | 0.298 |
| Sister/brother | 2 | 5 | 40.0 | 0.34 (0.06-2.03) | 0.239 |
| Grandparents | 17 | 29 | 58.6 | 0.88(0.33-2.40) | 0.809 |
| Other | | | | | |
| | | | | | |
| Adult index case | Infected cases, N | Total contacts, N | Secondary Attack Rates, % | OR (95% CI) | p-value |
| General transmission rate* | 393 | 581 | 67.6 | | |
| Contact Sex | | | | | |
| Female | 219 | 304 | 72 | 1.71 (1.13-2.57) | 0.01 |
| Male | 174 | 277 | 62.8 | Ref. | - |
| Contact age | | | | | |
| <18 y | 271 | 340 | 79.7 | Ref. | - |
| ≥18 y | 122 | 241 | 50.6 | 0.24 (0.17-0.35) | <0.001 |
| 18-39 y | 65 | 121 | 53.7 | | |
| 40-65 y | 49 | 103 | 47.6 | | |
| ≥65 y | 8 | 17 | 47.1 | | |
| Index case sex | | | | | |
| Female | 192 | 299 | 64.2 | 0.81 (0.51-1.29) | 0.374 |
| Male | 201 | 282 | 71.3 | Ref. | - |
| Case age | | | | | |
| 18-39 y | 207 | 304 | 68.1 | Ref. | - |
| 40-65 y | 183 | 272 | 67.3 | 0.89 (0.56-1.42) | 0.629 |
| ≥65 y | 3 | 5 | 60 | 1.44 (0.85-2.43) | 0.177 |
| Index case symptoms | | | | | |
| Yes | 382 | 565 | 67.6 | 0.75 (0.14-4.07) | 0.738 |
| No | 11 | 16 | 68.8 | Ref. | - |
| Family size | | | | | |

| | | | | | |
|------------------------|-----|-----|------|-------------------------|-------------|
| 4 or less | 218 | 296 | 73.6 | 1.59 (1.02-2.49) | 0.04 |
| More than 4 | 175 | 285 | 61.4 | Ref. | - |
| Relationship | | | | | |
| Partner | 88 | 164 | 53.7 | Ref. | - |
| Children | 270 | 343 | 78.7 | 0.81 (0.34-1.96) | 0.645 |
| Parents/parents in law | 14 | 26 | 53.8 | 1.76 (0.36-8.72) | 0.488 |
| Other | 21 | 48 | 43.8 | 0.44 (0.19-1.04) | 0.061 |

*p-value=0.006 in the comparison of secondary attack rate between pediatric and adult index cases

Accepted Manuscript

Figure legends

Figure 1. Study inclusions flow-chart.

Figure 2. Percentage of positive SARS-CoV-2 RT-PCRs in households by the age (pediatric versus adult) of the index cases.

Accepted Manuscript

Figure 1




Figure 2

